Open Access. Powered by Scholars. Published by Universities.®
Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 3 of 3
Full-Text Articles in Pharmacy and Pharmaceutical Sciences
Retrospective Study Of Warfarin Use In The Centracare Family Health Clinic, Lauren Martens, Jessica Lind
Retrospective Study Of Warfarin Use In The Centracare Family Health Clinic, Lauren Martens, Jessica Lind
Pharmacy Posters
Introduction:
- Warfarin is FDA approved for a variety of indications
- Recommended INR goal ranges can vary depending on indication
- Appropriate warfarin management is necessary for safety and efficacy of the medication
- Since November 2019, warfarin has been managed by the ambulatory pharmacist in the Family Health Clinic
Purpose:
- To further understand the patterns of use of warfarin within the CentraCare Family Health Clinic
- Specifically, determine the prevalence of warfarin indications and corresponding INR goals.
Evaluation Of Heparin-Induced Thrombocytopenia Antibody Laboratory Use And Anticoagulation Prescribing Patterns, Piper Swanson, Jesse Greenlee, Gregory Schaefer, Paul Huiras
Evaluation Of Heparin-Induced Thrombocytopenia Antibody Laboratory Use And Anticoagulation Prescribing Patterns, Piper Swanson, Jesse Greenlee, Gregory Schaefer, Paul Huiras
Pharmacy Posters
Introduction
- Heparin-induced thrombocytopenia (HIT) is a rare adverse reaction
- Calculating a 4T score prior to ordering a heparin-PF4 immunoassay is recommended. For a score < 4, HIT probability is low and an assay is not advised
- If high suspicion of HIT (4T greater than or equal to 4), an assay should be ordered, all heparin products discontinued, and a non-heparin anticoagulant initiated.
Purpose
- Determine if heparin immunoassay ordering was indicted according to retrospective 4T score
- Assess anticoagulation prescribing depending on the result of the assay
- Serve as a pre-group for a planned perverse post-HIT order set implementation analysis
Evaluation Of Antibiotic Use And Duration For Febrile Neutropenia, Kayla Jensen, Patricia Aubert, Joy Ward, Ann Wigton
Evaluation Of Antibiotic Use And Duration For Febrile Neutropenia, Kayla Jensen, Patricia Aubert, Joy Ward, Ann Wigton
Pharmacy Posters
Introduction:
- Febrile neutropenia (FN) affects over 80% of patients with hematologic cancer and 10% to 50% of patients with solid tumors
- National Comprehensive Cancer Network (NCCN) guidelines recommend empiric broad-spectrum monotherapy until the absolute neutrophil count (ANC) is over 500 cells/uL.
- Extended durations with broad-spectrum agents leads to increased risk of antibiotic resistance, toxicity and C. difficile infection.
Purpose
- To evaluate antibiotic prescribing patterns for patients with FN to optimize antibiotic stewardship.